HC Wainwright Analysts Boost Earnings Estimates for STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at HC Wainwright increased their Q2 2026 EPS estimates for Stoke Therapeutics in a note issued to investors on Friday, May 8th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of ($0.78) for the quarter, up from their prior estimate of ($0.83). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($3.28) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.09) EPS, FY2027 earnings at ($2.05) EPS and FY2028 earnings at ($0.67) EPS.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The business had revenue of $6.23 million during the quarter, compared to analyst estimates of $6.48 million.

Several other brokerages have also recently commented on STOK. Needham & Company LLC boosted their target price on Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Wedbush lifted their price target on Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Tuesday, March 17th. Wolfe Research initiated coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price objective on the stock. Guggenheim began coverage on Stoke Therapeutics in a report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, Chardan Capital reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.83.

Stoke Therapeutics Trading Down 0.5%

STOK opened at $32.49 on Wednesday. The business’s 50 day moving average is $34.15 and its 200-day moving average is $32.00. The stock has a market cap of $2.02 billion, a PE ratio of -11.56 and a beta of 1.20. Stoke Therapeutics has a twelve month low of $8.70 and a twelve month high of $40.22.

Insider Activity

In other Stoke Therapeutics news, CFO Thomas Leggett sold 2,382 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $74,651.88. Following the transaction, the chief financial officer directly owned 10,172 shares in the company, valued at approximately $318,790.48. The trade was a 18.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Adrian R. Krainer sold 33,243 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the sale, the director directly owned 283,302 shares in the company, valued at approximately $11,258,421.48. This trade represents a 10.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 69,699 shares of company stock worth $2,526,714. 9.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. Dimensional Fund Advisors LP boosted its stake in shares of Stoke Therapeutics by 19.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock valued at $32,229,000 after buying an additional 162,797 shares during the period. KBC Group NV acquired a new position in shares of Stoke Therapeutics in the first quarter worth $36,000. Swiss National Bank raised its holdings in shares of Stoke Therapeutics by 4.5% during the first quarter. Swiss National Bank now owns 79,100 shares of the company’s stock worth $2,575,000 after acquiring an additional 3,400 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Stoke Therapeutics by 1.9% during the first quarter. Bank of New York Mellon Corp now owns 143,407 shares of the company’s stock valued at $4,669,000 after purchasing an additional 2,605 shares during the last quarter. Finally, Candriam S.C.A. boosted its position in Stoke Therapeutics by 12.4% during the first quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock valued at $16,346,000 after purchasing an additional 55,330 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.